Abstract Library

#4153 Type 1 gastric neuroendocrine tumors (g-NETs) with vitamin B12 deficiency-caused nerve function damage – A case Report

Introduction: Patients with type 1 g-NETs frequently experience VitB12 deficiency as a result of autoimmune gastritis. VitB12 deficiency infrequently leads to neurological symptoms. Unfortunately, the delay in diagnosing this condition often results in prolonged suffering and increased financial burden for the patients.

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen X, Chen R, Cui L,

Keywords: type 1 gastric neuroendocrine tumor, vitamin B12 deficiency, nerve function damage, case report,

#4043 Treatments, clinicopathological characteristics and prognosis in thymic neuroendocrine tumors (TNETs): With especial reference to Temozolomide (TMZ)-based chemotherapy

Introduction: Thymic neuroendocrine tumors (TNETs) are rare but aggressive malignant neoplasms that exhibit significant heterogeneity. However, there is a paucity of comprehensive clinical studies conducted to investigate the prognosis of TNETs.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Cui L, Chen X, Zheng J,

Keywords: thymic neuroendocrine tumor, treatment, prognosis, temozolomide,

#3874 Ileum NET lost to follow-up due to COVID-19 pandemic presents with multiple metastases and severe carcinoid syndrome

Introduction: Small bowel neuroendocrine tumors (NETs) arise from the diffuse neuroendocrine system. These are often diagnosed as a result of acute symptomatology such as bowel obstruction and are the most common cause of carcinoid syndrome (CS) due to liver metastases (LM).

Conference:

Presenting Author:

Authors: Diculescu R, Becheanu G, Croitoru A, Poiana C,

Keywords: neuroendocrine tumor, carcinoid syndrome, carcinoid heart disease, Octreotide,

#3268 Management and treatment of neuroendocrine tumors during the global COVID-19 pandemic - Experience of medical oncology department of hospital 1st November

Introduction: The current recommendations for management of neuroendocrine tumor diseases are still evolving, due to the limited experience on this issue. As the new coronavirus can be transmitted through breath droplets, by contact, there is no consensus of how this fact may affect the investigation and treatment of neuroendocrine tumor diseases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Bengueddach A, Kaid M, Kehili H, Tidjene A, Bereksi Reguig F,

Keywords: neuroendocrine, covid-19, treatment,

#1256 Characterization and Rescue of a Pathogenic D63N Mutant Human Glucagon Receptor That Causes a Pancreatic Neuroendocrine Tumor Syndrome (Mahvash disease)

Introduction: We have previously demonstrated that inactivating glucagon receptor (GCGR) mutations cause a novel hereditary human disease of hyperglucagonemia, pancreatic α cell hyperplasia, and pancreatic neuroendocrine tumor (Mahvash disease). We recently identified a novel missense GCGR mutation, D63N, in a family with Mahvash disease.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Yu R

Authors: Yu R, Zhou C, Chen C,

Keywords: Mutant glucagon receptor, chaperone, Mahvash disease,